TicoVac Pediatric Side Effects

Generic name: tick-borne encephalitis (inactivated) pediatric vaccine

Note: This document provides detailed information about TicoVac Pediatric Side Effects associated with tick-borne encephalitis (inactivated) pediatric vaccine. Some dosage forms listed on this page may not apply specifically to the brand name TicoVac Pediatric.

Applies to tick-borne encephalitis (inactivated) pediatric vaccine: intramuscular suspension.

Important warnings This medicine can cause some serious health issues

Tell your doctor if you use other medicines or have other medical conditions or allergies.

Keep track of any and all side effects you have after receiving this vaccine. When you receive a booster dose, you will need to tell the doctor if the previous shot caused any side effects.

Becoming infected with tick-borne encephalitis is much more dangerous to your health than receiving this vaccine. However, like any medicine, this vaccine can cause side effects but the risk of serious side effects is low.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Common side effects may include:

• pain and tenderness where the vaccine was given;

• headache;

• fever;

• restlessness; or

• weakness.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report vaccine side effects to the US Department of Health and Human Services at 1 800 822 7967.

For healthcare professionals

Applies to tick-borne encephalitis (inactivated) pediatric vaccine: intramuscular suspension.

General

The most common side effects in children 1 through 15 years of age were local tenderness, local pain, headache, fever, and restlessness. The most common side effects in patients at least 16 years of age were local tenderness, local pain, fatigue, headache, and muscle pain.^[Ref]

Dermatologic

• Postmarketing reports: Dermatitis, erythema, hyperhidrosis, pruritus, rash (erythematous, maculopapular, vesicular), urticaria^[Ref]

Gastrointestinal

• Common (1% to 10%): Nausea, vomiting^[Ref]

Cardiovascular

• Postmarketing reports: Tachycardia^[Ref]

Hematologic

• Uncommon (0.1% to 1%): Swelling of lymph nodes, swelling of axillary/inguinal lymph nodes^[Ref]

Hypersensitivity

• Postmarketing reports: Anaphylactic reaction, hypersensitivity^[Ref]

Immunologic

• Postmarketing reports: Precipitation or aggravation of autoimmune disorders (e.g., multiple sclerosis)^[Ref]

Local

• Very common (10% or more): Injection site pain (up to 14.7%), tenderness (up to 29.9%)
• Common (1% to 10%): Injection site reactions (e.g., erythema, induration, swelling)
• Uncommon (0.1% to 1%): Hematoma
• Rare (0.01% to 0.1%): Ecchymosis, itching
• Postmarketing reports: Injection site joint movement impairment, injection site joint pain, injection site inflammation, injection site nodule^[Ref]

Metabolic

• Common (1% to 10%): Loss of appetite^[Ref]

Musculoskeletal

• Common (1% to 10%): Joint pain, muscle pain
• Postmarketing reports: Back pain, joint swelling, musculoskeletal stiffness (including neck stiffness), neck pain, pain in extremity^[Ref]

Nervous system

• Very common (10% or more): Headache (11.1%)
• Postmarketing reports: Aseptic meningitis, convulsion (including febrile), demyelinating disorders (acute disseminated encephalomyelitis, Guillain-Barré syndrome, myelitis, transverse myelitis), dizziness, encephalitis, meningism, polyneuropathy, sensory abnormalities and motor dysfunction (hemiparesis, hemiplegia, VIIth nerve paralysis/facial paresis, paralysis, paresis, neuritis, neuralgia, optic neuritis)^[Ref]

Ocular

• Postmarketing reports: Eye pain, photophobia, visual impairment^[Ref]

Other

• Common (1% to 10%): Fatigue, fever, malaise
• Postmarketing reports: Asthenia, chills, edema, disturbance, gait, herpes zoster (triggered in pre-exposed individuals), influenza-like illness, tinnitus^[Ref]

Rates of fever reported within 4 days after each dose in clinical trial study:

DOSE 1:

Children aged 1 to 2 years (n=186): 23.7% (38C to 38.4C [100.4F to 101.1F]); 5.9% (38.5C to 38.9C [101.2F to 102F]); 5.9% (39C to 40C [102.1F to 104F])

Children aged 3 to 6 years (n=563): 4.6% (38C to 38.4C [100.4F to 101.1F]); 5% (38.5C to 38.9C [101.2F to 102F]); 3% (39C to 40C [102.1F to 104F])

Children aged 7 to 15 years (n=1668): 3.4% (38C to 38.4C [100.4F to 101.1F]); 2% (38.5C to 38.9C [101.2F to 102F]); 0.3% (39C to 40C [102.1F to 104F])

Total (n=2417): 5.2% (38C to 38.4C [100.4F to 101.1F]); 3% (38.5C to 38.9C [101.2F to 102F]); 1.4% (39C to 40C [102.1F to 104F])

DOSE 2:

Children aged 1 to 2 years (n=185): 9.2% (38C to 38.4C [100.4F to 101.1F]); 2.2% (38.5C to 38.9C [101.2F to 102F]); 0.5% (39C to 40C [102.1F to 104F]); 0.5% (greater than 40C [greater than 104F])

Children aged 3 to 6 years (n=561): 1.2% (38C to 38.4C [100.4F to 101.1F]); 0.4% (38.5C to 38.9C [101.2F to 102F]); 0.5% (39C to 40C [102.1F to 104F])

Children aged 7 to 15 years (n=1664): 0.8% (38C to 38.4C [100.4F to 101.1F]); 0.4% (38.5C to 38.9C [101.2F to 102F]); less than 0.1% (39C to 40C [102.1F to 104F])

Total (n=2410): 1.6% (38C to 38.4C [100.4F to 101.1F]); 0.5% (38.5C to 38.9C [101.2F to 102F]); 0.2% (39C to 40C [102.1F to 104F]); less than 0.1% (greater than 40C [greater than 104F])

DOSE 3:

Children aged 1 to 2 years (n=184): 7.1% (38C to 38.4C [100.4F to 101.1F]); 3.8% (38.5C to 38.9C [101.2F to 102F]); 1.6% (39C to 40C [102.1F to 104F])

Children aged 3 to 6 years (n=557): 1.4% (38C to 38.4C [100.4F to 101.1F]); 0.4% (38.5C to 38.9C [101.2F to 102F]); 0.7% (39C to 40C [102.1F to 104F]); 0.2% (greater than 40C [greater than 104F])

Children aged 7 to 15 years (n=1649): 0.6% (38C to 38.4C [100.4F to 101.1F]); 0.3% (38.5C to 38.9C [101.2F to 102F]); 0.2% (39C to 40C [102.1F to 104F])

Total (n=2390): 1.3% (38C to 38.4C [100.4F to 101.1F]); 0.6% (38.5C to 38.9C [101.2F to 102F]); 0.5% (39C to 40C [102.1F to 104F]); less than 0.1% (greater than 40C [greater than 104F])^[Ref]

Fevers were very common in younger children and common in older children; Lower fever rates were reported after the second and third vaccinations compared to the first vaccination.

Psychiatric

• Common (1% to 10%): Changes in sleeping pattern, restlessness^[Ref]

Respiratory

• Postmarketing reports: Dyspnea^[Ref]

Further information

TicoVac Pediatric side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer